Log in or Sign up for Free to view tailored content for your specialty!
Hepatology News
NFL medical adviser tells physicians, like athletes, ‘the leader you’re looking for is you’
In his keynote address at this year’s Ending Clinician Burnout Global Summit, Thom Mayer, MD, FACEP, likened the health care practitioners in the audience to the professional football players he routinely treats.
VIDEO: Without universal screening, ‘tiny’ hepatitis D could ‘wreak havoc’ globally
In a Healio video exclusive, Edward V. Loftus Jr., MD, warned that, despite being the smallest virus capable of causing human disease, hepatitis delta virus holds an outsized global impact as the most severe form of viral hepatitis.
Log in or Sign up for Free to view tailored content for your specialty!
To identify, manage HDV, ‘the simple approach is to just screen’ all patients with HBV
Over recent years, there has been increased interest and attention to hepatitis delta virus, as we are beginning to understand that this is a real problem that at the moment is under-addressed and under-identified.
‘Uncommon’ but not ‘unimportant’: Screen all patients with hepatitis B for HDV
Despite being the smallest virus capable of causing human disease, it is estimated that up to 80% of patients with hepatitis delta virus will progress to liver cirrhosis and more than 50% will die of liver disease within 10 years of diagnosis.
Key elements to consider when buying equipment for your medical practice
As medical technology quickly evolves, practices in nearly all areas of medicine must frequently evaluate equipment upgrades and new purchases of new technology to stay at the forefront of patient care.
Neoadjuvant immunotherapy may broaden surgery eligibility for hepatocellular carcinoma
Neoadjuvant immunotherapy may allow more people with hepatocellular carcinoma to undergo surgical resection, according to retrospective study results.
Noninvasive model minimizes the risk for missing high-risk varices in unresectable HCC
A model using both clinical and imaging data predicted the absence of high-risk varices in patients with unresectable hepatocellular carcinoma and may help avoid unnecessary upper endoscopy in low-risk patients, research showed.
FDA approves Gilead’s Livdelzi for treatment of primary biliary cholangitis
Gilead’s Livdelzi, a selective peroxisome proliferator-activated receptor delta agonist, has received accelerated FDA approval for the treatment of primary biliary cholangitis, according to a company release.
HCV elimination efforts in Georgia lower infections by 61%, may advance reaching 2030 goal
A hepatitis C elimination program in Georgia reduced the estimated annual incidence of new infections by 61% since its launch in April 2015, which may accelerate efforts to reach the global 2030 elimination goal.
Tax-advantaged investing: Where to put your next dollar
As your paycheck grows, so does your discretionary spending and saving. While it is easy to spend, it is not always clear where to invest your next dollar intended for future spending.
-
Headline News
Study: Young patients hesitant to tell providers information their parents might see
November 06, 20242 min read -
Headline News
Q&A: Adults may know their risk for COPD with blood test
November 07, 20243 min read -
Headline News
CMS increases payment for dialysis facilities, includes oral-only drugs in the bundle
November 08, 20242 min read
-
Headline News
Study: Young patients hesitant to tell providers information their parents might see
November 06, 20242 min read -
Headline News
Q&A: Adults may know their risk for COPD with blood test
November 07, 20243 min read -
Headline News
CMS increases payment for dialysis facilities, includes oral-only drugs in the bundle
November 08, 20242 min read